Neurofilament Medium Chain is a protein encoded by the CDK5 gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
| Gene | [NEFM](/genes/nefm) |
|---|
| UniProt ID | [P12036](https://www.uniprot.org/uniprot/P12036) |
|---|
| PDB Structures | 1IDU, 2N3P, 4IPW |
|---|
| Molecular Weight | 102,476 Da |
|---|
| Subcellular Localization | Cytoplasm, Neuronal axons |
|---|
| Protein Family | Intermediate filament family |
|---|
The Neurofilament Medium Chain (NEFM) is a type IV intermediate filament protein expressed primarily in large myelinated axons. NEFM forms heteropolymers with neurofilament light chain (NEFL) and heavy chain (NEFH), creating the neurofilament triplet that provides structural support and regulates axonal caliber.
The protein contains:
- N-terminal head domain: phosphorylation-regulated
- Central alpha-helical rod domain: 310 residues, forms coiled-coil
- C-terminal tail domain: elongated, heavily phosphorylated, projects outward from the filament core
The phosphorylation of tail domain lysine-serine-proline (KSP) repeats regulates neurofilament spacing and axonal transport.
NEFM plays critical roles in the nervous system:
- Axonal Structure: Forms the core scaffold of large myelinated axons, particularly in motor neurons and sensory neurons
- Axonal Diameter Regulation: Phosphorylation state determines spacing between neurofilaments, influencing conduction velocity
- Fast Axonal Transport: Motor proteins (kinesins, dyneins) transport NEFM along microtubules
- Synaptic Function: Neurofilaments are present in presynaptic terminals, influencing neurotransmitter release
NEFM expression increases during development and is maintained in adult neurons. It is essential for maintaining axonal integrity and proper nerve conduction.
Dysregulation of NEFM is implicated in several neurodegenerative diseases:
- NEFM accumulation in NFTs correlates with disease progression
- Hyperphosphorylation leads to aggregation similar to tau
- CSF NEFM levels are elevated in AD patients and serve as a biomarker
- NEFM pathology observed in Lewy bodies
- Axonal degeneration precedes cell body loss
- NEFM fragments detected in PD CSF
- NEFM aggregation in motor neurons
- Mutations in NEFM (rare) cause Charcot-Marie-Tooth disease
- Dysregulated phosphorylation in sporadic ALS
- NEFM in glial cytoplasmic inclusions
- Oligodendrocyte dysfunction affects axonal transport
- CSF NEFM: FDA-approved biomarker for traumatic brain injury
- Blood NEFM: Emerging biomarker for AD, PD, and ALS progression
- Phosphorylated NEFM (pNfH) more specific for neurodegeneration
Current therapeutic approaches targeting neurofilaments:
- Biomarker Development: pNfH and NEFM in CSF/blood for diagnosis and clinical trials
- Phosphorylation Modulation: Kinase inhibitors (e.g., CDK5 inhibitors) to reduce abnormal phosphorylation
- Protein Aggregation Inhibitors: Small molecules to prevent NEFM aggregation
- Gene Therapy: NEFM expression modulation to restore axonal transport
- No direct NEFM-targeted drugs approved yet
- Neurofilament levels used as outcome measures in clinical trials for AD, ALS, and PD
- Perrot et al., Neurofilament markers in CSF and blood (2023)
- Khalil et al., Neurofilament light and medium chain in ALS (2022)
- Gaetani et al., Neurofilament phosphorylated heavy subunit as biomarker (2019)
- Lee et al., Neurofilament assembly and aggregation (2021)
- Bacioglu et al., Neurofilament in Alzheimer's disease (2016)
- CDK5 Gene
- Intermediate Filaments in Neurodegeneration
- Axonal Transport in Neurodegeneration